https://go.evvnt.com/1407814-0?pid=5248 The Westin Boston Seaport District
425 Summer Street
Boston, Massachusetts 02210
$Conference + Workshop Day: USD 4946.00, Conference Only: USD 2999.00
Lectures & Conferences
Returning for the 4th year, the Cell Therapy Analytical Development Summit is the leading industry-defining forum made exclusively for analytical, process development, CMC, QC, and regulatory experts.
New for 2022, take advantage of two tracks of content showcasing;
Pre-IND and Early Clinical Development
- Exploring Assay Development for Best-in-Class Early-Stage Characterization
- Establishing the Safety of Cell Therapy Products with Comprehensive Analytics
- Starting with the End-in-Mind: Considerations for Raw and Starting Material Analysis
- Optimizing Early-Stage Analytics to Bolster Speed to IND Submission and Phase 1 Launch
Clinical Development and Commercialization
- Improving Method Validation to Prepare for Successful Clinical Production
- Approaching Later-Stage Analytical and Process Technology Transfers
- Scaling Up from Clinical Development to Commercialization and Preparing for Release
- Optimizing Analytics During Manufacturing, Dealing with Process Changes
And don't miss out on all of our plenary presentations!
... as well as a variety of plenary presentations and pre-conference workshops to equip your team with the lessons learned to achieve success in analytical submission from pre-IND through to commercialization.
Learn from analytical trailblazers at BMS, Kite, Novartis, Takeda, and more to support your efforts in developing safe and effective cell therapies.
Speakers: Ana Giner Rubio, Adicet Bio, Yama Abassi, Agilent Technologies, PLXA Cell Analysis Division, Josephine Lembong, Alliance for Regenerative Medicine, Ajit Kamath, Beam Therapeutics, Alice Lin, Neogene Therapeutics, Amnon Eylath, Minovia Therapeutics, Anniesha Hack, Novartis, Anthony Leyme, Elevate Bio, Anu Vasudevan, Arsenal Bio, Benjamin Espen, Avobis Bio, Bo Yan, Beam Therapeutics, Chelsea Xue, Takeda, Hadar Adams, Atara Biotherapeutics, Ho-Tak Lau, Umoja Biopharma, Ho-Young Grace Lee, Kyverna Therapeutics, Isabelle Riviere, Memorial Sloan Kettering Cancer Center, James Piret, The University of British Columbia, James Richardson, Interius BioTherapeutics, Jenifer Kaplan, Novartis, Jenny Kim, Allogene Therapeutics, Jim Shaw, Chimeric Therapeutics, John Yu, Sana Biotechnology, Kim Luu, Talaris Therapeutics, Kruti Shah, Mnemo Therapeutics, Kyle Carter, Kite: A Gilead Company, Lantz Mackey, Novartis, Laura Pierce, National Institute of Standards and Technology, Leanne Jamieson, Notch Therapeutics, Mahwish Natalia, Takeda, Mallory Scott, Legend Biotech, Mandy Xie, Bristol Myers Squibb, Mariska ter Haak, IN8bio, Melba Marie Page, Moffitt Cancer Center, Minnal Gupta, University of Pennsylvania, Nathan Majewski, Celularity, Pete Cotter, Verve Therapeutics, Petra Pham, Bristol Myers Squibb, Richa Hanamsagar, Astellas Pharma, Sean Bradley, Catamaran Bio, Shibani Mitra-Kaushik, Takeda, Stephanie Mgebrof, Seattle Children's Hospital, Stephanie Woodall, KSQ Therapeutics, Sumeet Poudel, National Institute of Standards and Technology, Tam Soden, Kite: A Gilead Company, Taylor Zhang, Sana Biotechnology, Victor Lu, Innovative Cellular Therapeutics, Vidya Sundararaman, Poseida Therapeutic, Yan Gu, Takeda, Zhu Pirot, Bayer